Post on 05-Apr-2018
transcript
8/2/2019 15 Pharmacological Study
1/27
93
C. PHARMACOLOGICAL STUDY
8/2/2019 15 Pharmacological Study
2/27
94
PHARMACOLOGICAL STUDYTable 25
Name of Drug Mechanisms
of Action
Route/
Dosage
Indications Contraindications Side
Effects
Adverse
Effects
Nursing
Management
Generic Name:Diazepam
Brand Name:Valium
Classification:
AnxiolyticAntiepilepticBenzodiazepineSkeletal musclerelaxant(centrallyacting)
Exact mechanismof action notunderstood; actsmainly at thelimbic system andreticular formation;may act in spinalcord and at
supraspinal sitesto produce skeletalmuscle relaxation;potentiates theeffects of GABA,an inhibitoryneurotransmitter,anxioloytic effectsoccur at doseswell below those
necessary tocause sedation,ataxia; has littleeffect on corticalfunction.
Actual:
Ideal:Anxiety:2 10 mg IMor IV; repeatin 3-4 hours
if necessary
Alcoholwithdrawal:10mg IM orIv initially,then 5-10mg in 3-4hours ifnecessary
Managementof anxietydisorders orfor short-termrelief ofsymptoms ofanxiety.
Acute alcoholwithdrawal;may beuseful insymptomaticrelief of acuteagitation,tremor,deliriumtremens,
hallucinosis.
Contraindicatedwithhypersensitivity tobenzodiazepines;psychoses, acute-narrow angleglaucoma, shock,coma, acute
alcoholicintoxication;pregnancy (cleft lipor palate, inguinalhernia, cardiacdefects,microcephaly,pyloric stenosiswhen used in firsttrimester; neonatal
withdrawalsyndromwreported innewborns);lacatation.
Noted for:
DrowsinessDizzinessConfusionHeadacheAnxietyFatigue
DepressionInsomniaPhotophobiaCoughConstipationDry mouth
Noted for:
TremorParadoxicalexcitementOrthostatichypotensionHypotension
Monitor BP,PR,RR priorto periodicallythroughouttherapy andfrequentlyduring IVtherapy.
Assess IV sitefrequentlyduringadministration, diazepammay causephlebitis andvenousthrombosis.
Observedepressedpatientsclosely forsuicidaltendencies.
Observe andrecord
8/2/2019 15 Pharmacological Study
3/27
95
intensity,duration andlocation ofseizureactivity.Cautionpatient to
avoid takingalcohol orother CNSdepressantsconcurrentlywith thismedication.
8/2/2019 15 Pharmacological Study
4/27
96
PHARMACOLOGICAL STUDY
Table 26Name of Drug Mechanisms
of ActionRoute/Dosage
Indications Contraindications SideEffects
AdverseEffects
NursingManagement
Generic Name:Chlorpromazine
Brand Name:
Thorazine
Classification:AntiemeticAntipsychoticAnxiolyticDopamenergicblocker
Mechanism notfullyunderstood;antipsychotic
drugs blockpostsynapticdopaminereceptors in thebrain; depressthose parts ofthe braininvolved withwakefulnessand emesis;
anticholinergic,antihistamine(H1), and alphaadrenergicblocking.
Actual:100 mg 1 tabPO every 8hours
Ideal:75 200 mg/day PO
Managementofmanifestationsof psychotic
disorders;control ofmanic phaseof manicdepressiveillness.
Contraindicatedwith allergy tochlorpromazine,comatose or
severelydepressed states,bone marrowdepression,circulatorycollapse,subcortical braindamage,Parkinsonsdisease, liver
damage, cerebralor coronaryarteriosclerosis,severehypotension orhypertension.
Noted for:
DrowsinessInsomnia
HeadacheWeaknessTachycardiaBradycardiaBlurredvisionDry mouthSalivationNausea
Noted for:
SeizureExacerbation
of psychoticsymptomsExtraparamidalsyndromesHypotensionOrthostatichypotensionCardiac arrestHeart failure
Keep patientrecumbentfor 30minutes after
injection toavoidorthostatichypotension.
The patientsguardianshould beadvisedabout the
possibility oftardivedyskinesias.
Instruct theguardian toreport to thenurse stationif the clientexperiencing
8/2/2019 15 Pharmacological Study
5/27
97
sore throat,fever,unusualbleeding,rash,weakness,tremors, and
impairedvision.
8/2/2019 15 Pharmacological Study
6/27
98
PHARMACOLOGICAL STUDYTable 27
Name of Drug Mechanisms
of Action
Route/
Dosage
Indications Contraindications Side Effects Adverse
Effects
Nursing
Management
Generic Name:Ciprofloxacin
Brand Name:Ciloxan
Classification:Antibacterial
Fluoroquinolone
Bactericidal;interfereswith DNAreplication insusceptiblebacteriapreventingcell
reproduction.
Actual:500mg 1 tabBID
Ideal:500 700mg PO every12 hours
For thetreatment ofinfectionscaused bysusceptiblegram-negativebacteria,including E.
coli, P.mirabilis, K.pneumoniae,Enterobactercloacae, P.vulgaris, P.rettgeri, M.morganii, P.aeruginosa,Citrobacter
freundii, S.aureus, S.epidermidis,group Dstreptococci.
Contraindicatedwith allergy tociprofloxacin,norfloxacin or otherfluoroquinolones.
Noted for:
HeadacheNauseaDiarrheaHallucinationsHypersensitivity reaction
Confusion
Noted for:
CNS:Dizziness,insomnia,fatigue,depression,blurred vision.
GI: Vomiting,dry mouth,abdominalpain.
Hematologic:ElevatedBUN, AST,ALT, serum
creatinine andalkalinephosphatase;decreasedWBC,neutrophilcount,Hematocrit.
Ensure thatthe client iswelldehydrated.
Give antacidsto the clientatleast 2 hour
after dosing.
Instruct thesignificantother to giveplenty offluids to theclient whiletaking thisdrug.
Instruct thesignificantother toreport if theclient isexperiencingrash, visualchanges,weakness,
8/2/2019 15 Pharmacological Study
7/27
99
Others:Fever, rash
Watched for:
CV:Arrhythmias,hypotension,angina.
and tremors.
8/2/2019 15 Pharmacological Study
8/27
100
PHARMACOLOGICAL STUDY
Table 28Name of Drug Mechanisms
of ActionRoute/Dosage
Indications Contraindications Side Effects AdverseEffects
NursingManagement
GenericName:Omeprazole
Brand Name:LosecPrilosec
Classification:
AntisecretorydrugProton pumpinhibitor
Gastric acid-pumpinhibitor.Suppressesgastric acidsecretion byspecificinhibition ofthe hydrogen
potassiumATPaseenzymesystem at thesecretorysurface of thegastricparietal cells;blocks thefinal stage of
acidproduction.
Actual:20 mgone capOD
Ideal:60 mg POdaily
Shot-termtreatment forerosiveesophagitis andsymptomaticgastroesophagealreflux disease(GERD) poorlyresponsive to
other treatment.
Long-termtreatment ofpathologichypersecretoryconditions andactive duodenalcancer. It is amaintenance
healing of erosiveesophagitis.
Treatment of H.pylori associatedwith duodenalulcer and activebenign gastriculcers. It is alsoused in the
Contraindicatedwithhypersensitivity toomeprazole or itscomponents.
Noted for:
HeadacheDizzinessInsomniaApathyAnxietyDreamAbnormalities
DiarrheaAbdominalpainNauseaVomitingConstipationDry mouthCoughBack painFever
Noted for:
ParesthesiasTongueatrophyEpistaxis
Give the drugbefore meals.
Instruct theclient not tocrush or chewtablets,swallow whole.
Evaluate clientfor therapeuticresponse likerelief ofGastrointestinalsymptoms.
Instruct thesignificantother or
guardian to thenurse stationreport if theclientexperiencingsevereheadache,worsening ofsymptoms,fever, chills and
8/2/2019 15 Pharmacological Study
9/27
101
prevention andtreatment ofNSAID-inducedulcers.
severediarrhea.
8/2/2019 15 Pharmacological Study
10/27
102
PHARMACOLOGICAL STUDYTable 29
Name of Drug Mechanismsof Action
Route/Dosage
Indications Contraindications Side Effects Adverse Effects NursingManagement
Generic
Name:Esomeprazole
Brand Name:Nexum
Classification:AntisecretorydrugProton pump
inhibitor
Gastric acid-
pump inhibitor.Suppressesgastric acidsecretion byspecificinhibition of thehydrogenpotassiumATPaseenzyme
system at thesecretorysurface of thegastric parietalcells; blocksthe final step ofacidproduction; isbroken downless in the first
pass throughthe liver thanthe parentcompoundomeprazole,allowing forincreasedserum levels.
Actual:
40 mg onetab OD x 7days
Ideal:20 40 mgPO daily for4-8 weeks
Treatment
of GERDheartburnand othersymptoms.
Short termtreatment oferosiveesophagitis.
As part ofcombinationfortreatment ofduodenalulcerassociatedwithHelicobacterpylori.
Contraindicated
withhypersensitivity toomeprazole,esomeorazole, orother proton pumpinhibitor.
Noted for:
HeadacheDizzinessInsomniaAnxietyRashesDiarrheaNauseaAbdominalpain
VomitingConstipationDry mouthSinusitisCoughApathyVertigo
Noted for:
Tongue atrophyFlatulenceAlopeciaEpistaxisParesthesia
Assess for
hypersensitivityto any protonpump inhibitoror hepaticimpairment.
Instruct thesignificantother of theclient to take
drug at least 1hour beforemeals.
Instruct theclient or thesignificantother of theclient to reportif the client is
experiencingsevereheadache,worsening ofsymptoms,fever, chills,darkening ofthe skin, andchanges incolor of urine
8/2/2019 15 Pharmacological Study
11/27
103
and stool.
Instruct theclient or thesignificantother of theclient to limit
activities tothose that donot requirealertness andprecision asthe drug maycause vertigoand dizziness.
8/2/2019 15 Pharmacological Study
12/27
104
PHARMACOLOGICAL STUDYTable 30
Name of Drug Mechanisms ofAction
Route/Dosage
Indications Contraindications SideEffects
AdverseEffects
NursingManagement
GenericName:HydrocortisoneSodiumSuccinate
Brand Name:
Solu Cortef
Classification:AdrenocorticalsteroidCortecosteroid(short-acting)GlucocorticoidHormone
Enters targetcells and bindsto cytoplasmicreceptors;initiates manycomplexreactions that
are responsiblefor its anti-inflammatory,immuno-suppressive(glucocorticoid),and saltretaining(mineral-corticoid)
actions. Someactions may beundesirable,depending ondrug use.
Actual:250mg IVTTnow
Ideal:100 500 mginitially and
every 2, 4, or6 hoursbased oncondition andresponse
Replacementtherapy inadrenalcorticalinsufficiency.
Hyperthermia
associatedwith cancer.
Hematologicdisordersthrombocytopenic purpura,erythro-blastopenia.
Trichinosiswithneurologic ormyocardialinvolvement.
Contraindicatedwith allergy to anycomponent of thedrug, fungalinfections,amebiasis, hepatitisB, vaccine, or
varicella, andantibiotic resistantinfections, immuno-suppression.
Noted for:
VertigoHeadacheInsomniaMuscleweakness
Noted for:
SeizurePsychosisHypotensionShockSodium and
fluid retentionHypocalcemiaHypokalemiaIncreasedblood sugarIncreasedserumcholesterolAnaphylactoidor hyper-
sensitivityreactionsAtrophy atinjection site
Instruct theclient or thesignificantother of theclient to takewith meals orsnacks when
GI upsetoccurs to theclient.
8/2/2019 15 Pharmacological Study
13/27
105
PHARMACOLOGICAL STUDY
Table 31Name of Drug Mechanisms
of ActionRoute/Dosage Indications Contraindications Side
EffectsAdverseEffects
NursingManagement
GenericName:PotassiumChloride
Brand Name:
PotassiumChloride
Classification:Electrolyte
Principalintracellularcation of mostbody tissues,participates ina number of
physiologicprocessesmaintainingintracellulartonicity;transmissionof nerveimpulses;contraction ofcardiac,
skeletal, andsmoothmuscle;maintenanceof normalrenal function;also plays arole incarbohydrate
Actual:40 mEq IVTT
Ideal:40 80 mEq/L
Preventionandcorrection ofpotassiumdeficiency;when
associatedwith alkalosisusepotassiumchloride;whenassociatedwith acidosis,usepotassium
acetate,bicarbonate,citrate, orgluconate.
Treatment ofcardiacarrhythmiasdue to
Contraindicated withallergy to taatrazine,aspirin (tartrazine isfound in somepreaprationsmarketedas Kaon Cl, Klor -
Con); therapy withpotassium-sparingdiuretics oraldosteroneinhibiting agents;severe renalimpairment witholiguris, anuria,azotemia; untreatedAddisons disease,
hyperkalemia.
Noted for:
NauseaVomitingDiarrheaAbdominal
discomfort
Noted for:
GIobstructionGI bleedingGI ulceration
Hyperkalemia
Monitorplasmapotassiumlevels.
Monitor acid-
base balanceand ECG.
8/2/2019 15 Pharmacological Study
14/27
106
metabolismand variousenzymaticreactions.
cardiacglycosides.
8/2/2019 15 Pharmacological Study
15/27
107
PHARMACOLOGICAL STUDY
Table 32Name of Drug Mechanisms
of ActionRoute/Dosage Indications Contraindications Side Effects Adverse
EffectsNursingManagement
Generic
Name:Cefuroxime
Brand Name:CosefSufrexin
Classification:AntibioticCephalospirin
(secondgeneartion)
Bactericidal:
Inhibitssynthesis ofbacterial cellwall, causingcell death.
Actual:
750 mg IVTTq6 hours
Ideal:750 mg 1gIVTT q8 hours
Lower
respiratoryinfectionscaused by S.pneumoniae,S. aureus,E.coli,Klebsiellapneuemoniae,H. influenzae,and S.
pyogens.
Contraindicated
with allergy tocephalosporins orpenicillins.
Noted for:
HeadacheDizzinessLethargyNauseaVomitingAbdominalpainInflammationat IV site
Noted for:
HepatotoxicityNephrotoxicityBone marrowdepressionAnaphylaxisreaction
Discontinue if
hypersensitivityreactionoccurs.
Instruct theclient to avoidalcohol whiletaking the drugand for 3 daysafter because
severereactions oftenoccur.
Instruct theclient that hemayexperiencestomach upsetor diarrhea.
8/2/2019 15 Pharmacological Study
16/27
108
PHARMACOLOGICAL STUDYTable 33
Name of Drug Mechanismsof Action
Route/Dosage Indications Contraindications SideEffects
AdverseEffects
NursingManagement
GenericName:Acetaminophen
Brand Name:Paracetamol
Classification:Analgesic
Decreasesfever byinhibiting theeffects ofpyogens onthehypothalamicheatregulating
centers andby ahypothalamicaction leadingto sweatingandvasodilation.
Relievesfever by
inhibitingprostaglandinsynthesis atthe CNS butdoes nothave anti -inflammatoryactionbecause of itsminimal effect
Actual:500mg 1 tabq4PRN
Ideal:500mg 1 tabq4
Relief ofmild tomoderatepain,treatment offever.
Hypersensitivity;intolerance totartrazine, alcohol,table sugar.
Noted for:
DrowsinessNauseaVomitingAbdominalpain
Noted for:
HepatoxicityHepatic seizureRenal failureHypersensitivityDeliriumConvulsionsComa
Give the drugafter meal.
Advise thepatient to avoidalcohol; acutepoisoning withliver damagemay result.
Teach patient torecognize signsof chronicoverdose;bleeding,bruising,malaise, fever,sore throat.
Inform patientthat urine maybecome darkbrown as aresult ofphenacetin(metabolite ofacetaminophen).
Tell the patient
8/2/2019 15 Pharmacological Study
17/27
109
of peripheralprostaglandinsynthesis.
to notifyprescriber forpain or fever.
8/2/2019 15 Pharmacological Study
18/27
110
PHARMACOLOGICAL STUDYTable 34
Name of Drug Mechanismsof Action
Route/Dosage Indications Contraindications SideEffects
AdverseEffects
NursingManagement
GenericName:PotassiumChloride
Brand Name:Kalium durule
Classification:Electrolyte
Supplementalpotassium inthe form ofhigh potassiumfood orpotassiumchloride maybe able torestore normalpotassium
levels.
Actual:one tab T.I.D
Ideal:one tab B.I.D
To preventhypokalemia;prophylaxisduringtreatmentwith diuretics.
HyperkalemiaSevere renalimpairmentSevere haemolyticreactions
Noted for:
NauseaVomitingIrritability
Noted for:
HyperkalemiaMuscleweaknessDifficulty inswallowing
Administerwhile patient issitting up orstanding toprevent druginducedpsychosis.
Followinstruction
regardingdilution.
8/2/2019 15 Pharmacological Study
19/27
111
PHARMACOLOGICAL STUDY
Table 35Name of Drug Mechanisms
of ActionRoute/Dosage
Indications Contraindications SideEffects
AdverseEffects
NursingManagement
GenericName:PNSS
Classification:
Isotonic volumeexpander
Electrolytereplacement
NormalSaline is asterile,nonpyrogenicsolution forfluid andelectrolytereplinishment.
It contains noantimicrobialagents.
The pH is 5.0(4.5 to 7.0).
It contains 9g/L SodiumChloride with
an osmolarityof 308mOsmol/L.
It contains154 mEq/LSodium andChloride.
.
Actual:PNSS 1L@ 100cc/h
Ideal:20cc/kg oflean bodyweight forhypovolemi
chypotension. Repeatonce PRN.
It is indicatedas a source ofwater andelectrolytes.
In general,intravenouslines shouldnot be started
unless thepatientcurrently, ormay soonneed eitherfluidreplenishmentor medicationadministration.
If used toreplenishfluids, a largebore IV (18Gor more)should bestarted, hungwith a 1000mL bag of
SevereHypertensionPulmonary edema
No sideeffectsnoted.
Reactionswhich mayoccurbecause ofthe solutionor thetechnique ofadministration include
febrileresponse,infection atthe site ofinjection,venousthrombosis orphlebitisextendingfrom the site
of injection,extravasation, andhypervolemia.
If an adversereaction doesoccur,discontinue
Observe ten rights ingiving medications.
Performhandwashing beforegiving medications.
8/2/2019 15 Pharmacological Study
20/27
112
saline.
If saline isbeing startedfor medicationadministrationmaintain at
TKVO, orconsider usinga saline lockinstead ofintravenousline.
the infusion,evaluate thepatient,instituteappropriatetherapeuticcountermeas
ures andsaveremainder ofthe fluid forexaminationif deemednecessary.
8/2/2019 15 Pharmacological Study
21/27
113
PHARMACOLOGICAL STUDYTable 36
Name of Drug Mechanismsof Action
Route/Dosage
Indications Contraindications Side Effects Adverse Effects NursingManagement
GenericName:PLR
Classification:
Hypertonicvolume
expander
Electrolytereplacement
IV hypertonicsaline (HS)induces ashift of fluidfrom theintracellular totheextracellualrspace across
the osmoticgradient itgenerates.
It thereforereduces brainwater,increasesblood volumeand increasesplasmasodium. Notethatintracellularvolumeis inverselyproportionalto plasmasodiumconcentration
Actual:PLR 1L@20gtts/min
Ideal:
Osmotherapeutic agentfortreatment ofcerebraloedemaand raisedintracranialpressure
(eg headinjury,DKA).
Treatmentofsymptomatichyponatraemicseizures.
Smallvolumeresuscitation for shock(e.g.associatedwithtraumatic
Pre-existingplasmatichyperosmolarity -dehydration withextracellularpredominance.
Anuria due tosevere renal
disease, severepulmonarycongestion or frankpulmonary edema;active intracranialbleeding exceptduring craniotomy;progressive renaldamage ordysfunction afterinstituting mannitoltherapy, includingincreasing oliguriaand azotemia;progressive heartfailure or pulmonarycongestion afterinstituting mannitoltherapy.
HypertensionTachycardiaThirstOliguriaThrombophlebitisShiversFeverUrticaria
NauseaVomiting
Failure torecognize severeimpairment ofrenal functionwith the highlikelihood ofnondiurecticresponse can leadto aggravateddehydration of
tissues andincreased vascularfluid load.
Induced diuresis inthe presence ofpreexistinghemoconcentration and preexistingdeficiency of water
and electrolytescan lead to seriousimbalances.
Expansion of theextracellular spacecan aggravatecardiacdecompensationor induce it in the
Observe tenrights in givingmedications.
Performhandwashingbefore givingmedications.
8/2/2019 15 Pharmacological Study
22/27
114
head injury)or as asrenoprotective agent(e.g.preventionof
radiocontrast andcytotoxicnephropathy,rhabdomyolysisinducedrenalfailure)
presence of latentheart failure.Pulmonarycongestion oredema can beseriouslyaggravated withthe expansion ofthe extracellularand thereforeintravascular fluidload.
Hemodilution anddilution of theextracellular fluidspaceby osmotic shift of
water can induceor aggravatepreexistinghyponatremia.If unrecognized,such fluid and/orelectrolyte shiftcanproduce thereported adversereactions ofpulmonarycongestion,acidosis,electrolyte loss,dryness of mouth,thirst, edema,head ache, blurredvision, convulsionsand congestive
8/2/2019 15 Pharmacological Study
23/27
115
cardiac failure..
8/2/2019 15 Pharmacological Study
24/27
116
SUMMARY OF MEDICATION ADMINISTRATION RECORD
Table 37
DateOrdered
Time Name of Drug &Preparation
Generic Name (Brand
Name)
Classification Dosage Route Frequency
02/13/2012 6:05pm Diazepam (Valium ) AnxiolyticAntiepileptic
BenzodiazepineSkeletal muscle
relaxant (centrallyacting)
5mg IVTT q6
8:45pm Chlorpromazine(Thorazine)
AntiemeticAntipsychotic
Anxiolytic
Dopamenergicblocker
100mg 1tab
PO now
02/14/2012 4:00am12:00noon
Chlorpromazine(Thorazine)
AntiemeticAntipsychotic
AnxiolyticDopamenergic
blocker
100mg 1tab
PO q8
10:30am Omeprazole (Losec) Antisecretory drugProton pump inhibitor
20mg 1 cap PO O.D
02/15/2011 10:00am Omeprazole (Losec) Antisecretory drug
Proton pump inhibitor
20mg 1 cap PO O.D
10:00am Chlorpromazine(Thorazine)
AntiemeticAntipsychotic
AnxiolyticDopamenergic
blocker
100mg 1tab
PO O.D
10:00am3:00pm8:00pm
Potassium Chloride(Kalium Dunule)
Electrolyte 1 tab PO T.I.D
8/2/2019 15 Pharmacological Study
25/27
117
10:00am Chlorpromazine(Thorazine)
AntiemeticAntipsychotic
AnxiolyticDopamenergic
blocker
100mg 1tab
PO O.D
10:00am Omeprazole (Losec) Antisecretory drugProton pump inhibitor
20mg 1 cap PO O.D
12noon Acetaminophen(Paracetamol)
Analgesic 500mg 1tab
PRN Q4
02/16/2012 10:00am Cefuroxime (Cosef) AntibioticCephalospirin
(second geneartion)
750mg IVTT q6
8:00am6:00pm
Ciprofloxacin (Ciloxan) AntibacterialFluoroquinolone
500mg 1tab
PO B.I.D
11:30am Hydrocortisone (SoluCortef)
Adrenocorticalsteroid
Cortecosteroid
(short-acting)Glucocorticoid
Hormone
250mg IVTT now
8:00am1:00pm6:00pm
Potassium Chloride(Kalium Dunule)
Electrolyte 1 tab PO T.I.D
10:00am Chlorpromazine(Thorazine)
AntiemeticAntipsychotic
AnxiolyticDopamenergic
blocker
100mg 1 PO O.D
(Thorazine) tab10:00am Omeprazole (Losec) Antisecretory drug
Proton pump inhibitor20mg 1 cap PO O.D
5:00pm Acetaminophen(Paracetamol)
Analgesic 500mg 1tab
PRN q4
02/17/2012 10:00am3:00pm8:00pm
Potassium Chloride(Kalium Dunule)
Electrolyte 1 tab PO T.I.D
8/2/2019 15 Pharmacological Study
26/27
118
8:00am6:00pm
Ciprofloxacin (Ciloxan) AntibioticCephalospirin
(second geneartion)
500mg 1tab
PO B.I.D
10:00am Cefuroxime (Sufrexin) AntibioticCephalospirin
(second geneartion)
750mg IVTT q6
10:00am
6:00pm
Chlorpromazine
(Thorazine)
Antiemetic
AntipsychoticAnxiolytic
Dopamenergicblocker
100mg 1
tab
PO O.D
11:15am Hydrocortisone (SoluCortef)
Adrenocorticalsteroid
Cortecosteroid(short-acting)Glucocorticoid
Hormone
250mg IVTT now
02/18/2012 10:00am3:00pm8:00pm
Potassium Chloride(Kalium Dunule)
Electrolyte 1 tab PO T.I.D
8:00am6:00pm
Ciprofloxacin (Ciloxan) AntibacterialFluoroquinolone
500mg 1tab
PO B.I.D
2:30am Chlorpromazine(Thorazine)
AntiemeticAntipsychotic
AnxiolyticDopamenergic
blocker
100mg 1tab
PO B.I.D
10:00am6:00pm
Chlorpromazine(Thorazine)
AntiemeticAntipsychotic
AnxiolyticDopamenergic
blocker
100mg 1tab
PO q8
10:00am Omeprazole (Losec) Antisecretory drugProton pump inhibitor
20mg 1 cap PO O.D
6:00pm12midnight
Potassium Chloride(Kalium Dunule)
Electrolyte 1 tab PO q6
8/2/2019 15 Pharmacological Study
27/27
119
8:00am1:00pm
Potassium Chloride(Kalium Dunule)
Electrolyte 1 tab PO T.I.D
02/19/2012 8:00am Ciprofloxacin (Ciloxan) AntibacterialFluoroquinolone
500mg 1tab
PO B.I.D
10:00am Omeprazole (Losec) Antisecretory drug
Proton pump inhibitor
20mg 1 cap PO O.D
6:00am2:00pm6:00pm
Chlorpromazine(Thorazine)
AntiemeticAntipsychotic
AnxiolyticDopamenergic
blocker
100mg 1tab
PO q8
6:00am12noon6:00pm
12midnight
Potassium Chloride(Kalium Dunule)
Electrolyte 1 tab PO q6
02/20/2012 6:00am12noon
Potassium Chloride(Kalium Dunule)
Electrolyte 1 tab PO q6
2:00am10:00pm
Chlorpromazine(Thorazine)
AntiemeticAntipsychotic
AnxiolyticDopamenergic
blocker
100mg 1tab
PO q8
10:00am Omeprazole (Losec) Antisecretory drugProton pump inhibitor
20mg 1 cap PO O.D